Homeland Security and Governmental Affairs Committee
Introduced
In Committee
On Floor
Passed Chamber
Enacted
Pharmaceutical Regulation Conflict of Interest Act This bill amends the Ethics in Government Act of 1978 to prohibit a pharmaceutical regulator from using his or her position as regulator to influence any matter that provides a direct or substantial pecuniary benefit to a former employer or client. The position of pharmaceutical regulator refers to any officer or employee occupying a supervisory position within the Drug Enforcement Administration or the Food and Drug Administration. The bill also prohibits such a pharmaceutical regulator from participating in matters involving an individual or entity with whom the pharmaceutical regulator is negotiating future employment. The bill expands restrictions on lobbying by such pharmaceutical regulators following separation from employment with a pharmaceutical regulatory agency.
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in Senate
Read twice and referred to the Committee on Homeland Security and Governmental Affairs.
Introduced in Senate
Read twice and referred to the Committee on Homeland Security and Governmental Affairs.
Government Operations and Politics
A bill to prevent conflicts of interest that stem from the revolving door that raises concerns about the independence of pharmaceutical regulators.
USA115th CongressS-2057| Senate
| Updated: 11/1/2017
Pharmaceutical Regulation Conflict of Interest Act This bill amends the Ethics in Government Act of 1978 to prohibit a pharmaceutical regulator from using his or her position as regulator to influence any matter that provides a direct or substantial pecuniary benefit to a former employer or client. The position of pharmaceutical regulator refers to any officer or employee occupying a supervisory position within the Drug Enforcement Administration or the Food and Drug Administration. The bill also prohibits such a pharmaceutical regulator from participating in matters involving an individual or entity with whom the pharmaceutical regulator is negotiating future employment. The bill expands restrictions on lobbying by such pharmaceutical regulators following separation from employment with a pharmaceutical regulatory agency.